Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Mary Tagliaferri resigned as Director at RayzeBio, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
each of Richard Heyman, PhD, Tim Van Hauwermeiren, Maha Katabi, PhD, Yi Larson, Christy Oliger, Ken Song, MD, Mary Tagliaferri, MD, and Angie You, PhD resigned as a director of the Company
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Benjamin Hickey was appointed as President at RayzeBio, Inc..
- Action
- appointed
- Role
- President
Exact text from the filing
Benjamin Hickey was appointed to serve as President of the Company
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Sophia Park was appointed as Vice President at RayzeBio, Inc..
- Action
- appointed
- Role
- Vice President
Exact text from the filing
Sophia Park was appointed to serve as a Vice President of the Company
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Ken Song resigned as Director at RayzeBio, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
each of Richard Heyman, PhD, Tim Van Hauwermeiren, Maha Katabi, PhD, Yi Larson, Christy Oliger, Ken Song, MD, Mary Tagliaferri, MD, and Angie You, PhD resigned as a director of the Company
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Angie You resigned as Director at RayzeBio, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
each of Richard Heyman, PhD, Tim Van Hauwermeiren, Maha Katabi, PhD, Yi Larson, Christy Oliger, Ken Song, MD, Mary Tagliaferri, MD, and Angie You, PhD resigned as a director of the Company
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Tim Van Hauwermeiren resigned as Director at RayzeBio, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
each of Richard Heyman, PhD, Tim Van Hauwermeiren, Maha Katabi, PhD, Yi Larson, Christy Oliger, Ken Song, MD, Mary Tagliaferri, MD, and Angie You, PhD resigned as a director of the Company
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Sandra Ramos-Alves was appointed as Director at RayzeBio, Inc..
- Action
- became director
- Role
- Director
Exact text from the filing
the directors of Purchaser as of immediately prior to the Effective Time, which consisted of Konstantina Katcheves, Sandra Ramos-Alves and Kimberly M. Jablonski, became the directors of the Company
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Scott Matarese was appointed as Vice President at RayzeBio, Inc..
- Action
- appointed
- Role
- Vice President
Exact text from the filing
Scott Matarese was appointed to serve as a Vice President of the Company
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Richard Heyman resigned as Director at RayzeBio, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
each of Richard Heyman, PhD, Tim Van Hauwermeiren, Maha Katabi, PhD, Yi Larson, Christy Oliger, Ken Song, MD, Mary Tagliaferri, MD, and Angie You, PhD resigned as a director of the Company
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Christy Oliger resigned as Director at RayzeBio, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
each of Richard Heyman, PhD, Tim Van Hauwermeiren, Maha Katabi, PhD, Yi Larson, Christy Oliger, Ken Song, MD, Mary Tagliaferri, MD, and Angie You, PhD resigned as a director of the Company
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Kimberly M. Jablonski was appointed as Director at RayzeBio, Inc..
- Action
- became director
- Role
- Director
Exact text from the filing
the directors of Purchaser as of immediately prior to the Effective Time, which consisted of Konstantina Katcheves, Sandra Ramos-Alves and Kimberly M. Jablonski, became the directors of the Company
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Sandra Ramos-Alves was appointed as Vice President and Treasurer at RayzeBio, Inc..
- Action
- appointed
- Role
- Vice President and Treasurer
Exact text from the filing
Sandra Ramos-Alves was appointed to serve as a Vice President and Treasurer of the Company
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Konstantina Katcheves was appointed as Director at RayzeBio, Inc..
- Action
- became director
- Role
- Director
Exact text from the filing
the directors of Purchaser as of immediately prior to the Effective Time, which consisted of Konstantina Katcheves, Sandra Ramos-Alves and Kimberly M. Jablonski, became the directors of the Company
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Yi Larson resigned as Director at RayzeBio, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
each of Richard Heyman, PhD, Tim Van Hauwermeiren, Maha Katabi, PhD, Yi Larson, Christy Oliger, Ken Song, MD, Mary Tagliaferri, MD, and Angie You, PhD resigned as a director of the Company
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Kimberly M. Jablonski was appointed as Vice President and Secretary at RayzeBio, Inc..
- Action
- appointed
- Role
- Vice President and Secretary
Exact text from the filing
Kimberly M. Jablonski was appointed to serve as a Vice President and Secretary of the Company
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Maha Katabi resigned as Director at RayzeBio, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
each of Richard Heyman, PhD, Tim Van Hauwermeiren, Maha Katabi, PhD, Yi Larson, Christy Oliger, Ken Song, MD, Mary Tagliaferri, MD, and Angie You, PhD resigned as a director of the Company
View on SEC.gov
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
RayzeBio, Inc.: Bylaws amended and restated in their entirety pursuant to Merger Agreement at Effective Time.
- Change
- bylaw amendment
Exact text from the filing
the Company’s certificate of incorporation and bylaws were amended and restated in their entirety, as set forth in Exhibits 3.1 and 3.2, respectively, to this Current Report on Form 8-K and are incorporated herein by reference.
View on SEC.gov
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
RayzeBio, Inc.: Certificate of incorporation amended and restated in its entirety pursuant to Merger Agreement at Effective Time.
- Change
- charter amendment
Exact text from the filing
the Company’s certificate of incorporation and bylaws were amended and restated in their entirety, as set forth in Exhibits 3.1 and 3.2, respectively, to this Current Report on Form 8-K and are incorporated herein by reference.
View on SEC.gov
M&A Transactions
SEC 8-K Item 2.01/5.01
confidence 0.9
RayzeBio, Inc. underwent a change of control involving Bristol-Myers Squibb Company for $62.50 per Share in cash (closed 2024-02-26).
- Action
- change of control
- Counterparty
- Bristol-Myers Squibb Company
- Consideration
- $62.50 per Share in cash
- Closing
- 2024-02-26
Exact text from the filing
Purchaser commenced a tender offer to acquire all of the outstanding shares of common stock of the Company, par value $0.0001 per share (the “ Shares ”), at an offer price of $62.50 per Share in cash (the “ Offer Price ”), without interest, subject to any applicable withholding of taxes, upon the terms and subject to the conditions set forth in the Offer to
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.